Array BioPharma
Oncology deal signed for development of orally active MEK inhibitor
Published in Law and Health Weekly, January 12th, 2004
The program includes the clinical development candidate (ARRY-142886) and related intellectual property.
Under the agreement, Array will receive an upfront payment of $10 million, research funding, potential development milestones of over $85 million (dependent upon the number of successfully commercialized products), and royalties on product sales. Array plans to file an investigational new drug application (IND) and initiate a phase I clinical trial during 2004.
AstraZeneca...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Matritech
Patricia Randall becomes VP and general counsel of cancer diagnostics company - BioVisioN AG
Peptidomics company names new chief scientific officer - Birmingham Heartlands Hospital
A new line probe assay identifies hepatitis B virus precore variants in sera - Bloomberg School of Public Health
Children get better care with developmental specialists on physician team - Boston Biomedica, Inc.
Diagnostic kit gets FDA approval - Boston University
Antibody- and RNA-based HIV testing should be offered to suspected patients - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
